drugset / Trial / NCT05156554

PEG-rhG-CSF Compared With rhG-CSF in Lymphoma Patients After Autologous Hematopoietic Stem Cell Transplantation

NCT05156554

RandomizedParallel-groupOpen-labelTreatment

Summary

The purpose of the study is to evaluate the efficacy and safety of PEG-rhG-CSF compared with rhG-CSF on the recovery of hematopoietic function after autologous stem cell transplantation in patients with lymphoma.

Timeline

Start
2021-12
Primary completion
2022-12
Completion
2023-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Pegfilgrastim Protein / enzyme biologic 6 mg
Comparator filgrastim Protein / enzyme biologic 5 ug/kg

Indications